ArticleHaematologica2011
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
Article in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 90 citations in OpenAlex.
- Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.Blood advances · 2022Trial
- Evolution of mast cell research associated with the Laboratory of Allergic Diseases, 1985-2022: Summary of the 2023 NIAID Symposium.The Journal of allergy and clinical immunology · 2025Review
- Systemic mastocytosis: current status and challenges in 2024.Blood advances · 2025Review
- Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment.Genes · 2024Review
- Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.International journal of molecular sciences · 2023Review
- MITF Downregulation Induces Death in Human Mast Cell Leukemia Cells and Impairs IgE-Dependent Degranulation.International journal of molecular sciences · 2023Article
- CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition inCancers · 2022Article
- Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.Cancers · 2022Review
- Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.HemaSphere · 2021Review
- Top-Down Proteomics of Human Saliva Discloses Significant Variations of the Protein Profile in Patients with Mastocytosis.Journal of proteome research · 2020Article
- Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts.Theranostics · 2020Review
- Article
- Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.International journal of molecular sciences · 2019Review
- Impact of somatic and germline mutations on the outcome of systemic mastocytosis.Blood advances · 2018Article
- CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.Blood · 2018Article
- Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.Current hematologic malignancy reports · 2018Review
- The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.Haematologica · 2018Article
- Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.Leukemia · 2018Article
- Midostaurin: a magic bullet that blocks mast cell expansion and activation.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Cooperating genetic events are likely to contribute to the phenotypic diversity of KIT-D816V systemic mastocytosis. In this study, 44 patients with KIT-D816V systemic mastocytosis were evaluated for coexisting NRAS, KRAS, HRAS or MRAS mutations. Activating NRAS mutations were identified in 2 of 8 patients with advanced disease. NRAS mutations were not found in patients with indolent systemic mastocytosis. To better understand the clonal evolution of mastocytosis, we evaluated the cell compartments impacted by the NRAS and KIT mutations. Clonal mast cells harbored both mutations. KIT-D816V was not detected in bone marrow CD34(+) progenitors, whereas the NRAS mutation was present. These findings suggest that NRAS mutations may have the potential to precede KIT-D816V in clonal development. Unlike other mature lineages, mast cell survival is dependent on KIT and the presence of these two activating mutations may have a greater impact on the expansion of this cell compartment and in resultant disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.